person · Reporting owner

SIMMONS DAVID S

Disclosed activity across 4 companies

Tapewire entity: 16752
SEC CIK: 0001508519

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ACCENDRA HEALTH INC/VA/OMI · Entity 6858	Director	March 30, 2018	April 02, 2018
Viatris IncVTRS · Entity 3277	Director	September 30, 2026	October 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ACCENDRA HEALTH INC/VA/

Report date March 30, 2018 · Filed April 02, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom StockSEC Table II · derivative / convertible security	Direct	3,197	Reported balance After 2018-03-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-03-30 · Grant · Acquired 54 · Balance 3,197 F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d). F2: Shares acquired through quarterly dividend reinvestment transaction.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of phantom stock are convertible on a 1-for-1 basis and become payable, in cash or common stock, at the election of the reporting person, upon the occurrence of one of the following (as elected in advance by the reporting person): (a) death, (b) disability, (c) termination of service as director, (d) specified future delivery date, or (e) the earliest to occur of (a), (b), (c) or (d).

F2: Shares acquired through quarterly dividend reinvestment transaction.

Viatris Inc

Report date September 30, 2026 · Filed October 02, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Deferred Stock UnitsSEC Table II · derivative / convertible security	Direct	4,479	Reported balance After 2026-09-30 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-09-30 · Grant · Acquired 2,117 · Balance 4,479 F1: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control.
Dividend Equivalent DSUsSEC Table II · derivative / convertible security	Direct	16.6533	Reported balance Holding disclosure · report date 2026-09-30 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance 16.6533 F2: Represents dividend equivalent DSUs that accrued with respect to DSUs previously granted to the reporting person with respect to the election to receive payment of quarterly director fees in the form of DSUs and vest on the same schedule as the underlying DSUs. Amount represents dividend equivalent DSUs that accrued with respect to such DSUs in transactions exempt from Section 16 under Rule 16a-11.

Filing footnotes · ownership attribution and instrument terms

F1: On September 30, 2026, the reporting person was automatically granted 2,117 deferred stock units (DSUs) pursuant to the reporting person's election to receive payment of quarterly non-employee director fees in the form of DSUs. This grant was made in lieu of cash fees, based on the September 30, 2026 closing price of $17.72 per share of common stock of Viatris Inc. (Viatris). Each DSU is fully vested and represents the right to receive one share of common stock of Viatris. The DSUs settle in shares of common stock upon the earliest of the reporting person's termination of service as a non-employee director, the reporting person's death or disability, or a change in control.

F2: Represents dividend equivalent DSUs that accrued with respect to DSUs previously granted to the reporting person with respect to the election to receive payment of quarterly director fees in the form of DSUs and vest on the same schedule as the underlying DSUs. Amount represents dividend equivalent DSUs that accrued with respect to such DSUs in transactions exempt from Section 16 under Rule 16a-11.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PFIZER INC

Report date May 31, 2012 · Filed June 01, 2012

Section 16 reporting ended · disclosed 2012-06-01. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible security	Direct	11,121	Reported balance After 2012-05-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2012-05-31 · Grant · Acquired 77 · Balance 11,121 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-12-08 transaction · row 5 3 source rows · reconciled sequence Row 1 · 2021-12-08 · Disposition to issuer · Disposed 469,999 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration"). Row 4 · 2021-12-08 · Grant · Acquired 300,912 · Balance 300,912 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. Row 5 · 2021-12-08 · Disposition to issuer · Disposed 300,912 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger. F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.
Common StockSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2021-12-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-08 · Disposition to issuer · Disposed 120,000 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Family Trust	0	Reported balance After 2021-12-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 3 · 2021-12-08 · Disposition to issuer · Disposed 570,760 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.05 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-08 · Disposition to issuer · Disposed 2,318,799 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F4: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	2,092,413	Reported balance After 2021-12-08 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-08 · Grant · Acquired 385,441 · Balance 2,092,413 F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.59 · Expires 2027-05-11	Direct	0	Reported balance After 2021-12-08 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-12-08 · Disposition to issuer · Disposed 2,092,413 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $37.22 · Expires 2031-02-11	Direct	0	Reported balance After 2021-12-08 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-12-08 · Disposition to issuer · Disposed 343,347 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F6: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement. F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

F3: Prior to the Merger, the Reporting Person held certain restricted stock units subject to performance-based vesting criteria ("PSUs") which were not included on prior reports as the performance-based vesting criteria had not been satisfied. At the effective time of the Merger, each unvested PSU was canceled and converted into a restricted stock unit with substantially the same terms as were applicable to such PSU immediately prior to the effective time of the Merger (other than performance-based vesting conditions) with respect to a number of shares of Buyer equal to the product of (a) the Merger Consideration divided by the price of Buyer stock prior to the Merger, as determined in accordance with the Merger Agreement (the "Exchange Ratio") and (b) the number of shares of Issuer common stock subject to such PSU, based on the actual level of performance deemed achieved prior to the Merger.

F4: These options, of which 385,438 were unvested and scheduled to vest on May 11, 2022, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F5: These options, of which (i) 996,824 options were eligible to vest upon the achievement of certain return on capital or rate of return conditions three years after the initial public offering of the Issuer or earlier, upon certain sales by significant stockholders, and (ii) 385,441 options were eligible to vest upon the achievement of certain EBITDA-based vesting conditions for the fiscal year 2021 and were not included on prior reports as the performance-based vesting criteria had not been satisfied, were canceled in the Merger in exchange for a cash payment per underlying share equal to the difference between the exercise price of the option and the Merger Consideration.

F6: This option, which provided for vesting in four equal installments beginning on February 11, 2022, was canceled and converted into an option to purchase a number of shares of Buyer common stock equal to the number of shares of Issuer common stock subject to such option multiplied by the Exchange Ratio, at a price per share equal to the exercise price per share divided by the Exchange Ratio, plus a cash payment in respect of any fractional shares as provided in the Merger Agreement.

F7: Following the closing of the Merger, the Reporting Person's employment was terminated and the vesting of unvested equity awards of Buyer will be accelerated pursuant to the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 08, 2016 Filed Dec 21, 2016 19:49 UTC	ACCENDRA HEALTH INC/VA/ OMI · Entity 6858	GiftCommon Stock	2,200	$0.00	$0.00	Disclosure SEC source: 0000075252-16-000228 · edgar.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,316 Read SEC document
May 31, 2012 Filed Jun 1, 2012 21:35 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	77	$21.87	$1,683.99	Disclosure SEC source: 0001225208-12-013548 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,121 Underlying: Common Stock · 77 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
May 15, 2012 Filed May 16, 2012 19:32 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	167	$22.30	$3,724.10	Disclosure SEC source: 0001225208-12-012558 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,044 Underlying: Common Stock · 167 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 30, 2012 Filed May 1, 2012 20:59 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	84	$22.90	$1,923.60	Disclosure SEC source: 0001225208-12-010670 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,877 Underlying: Common Stock · 84 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 13, 2012 Filed Apr 16, 2012 22:07 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	71	$21.85	$1,551.35	Disclosure SEC source: 0001225208-12-009838 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,793 Underlying: Common Stock · 71 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 30, 2012 Filed Apr 3, 2012 18:56 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	74	$22.65	$1,676.10	Disclosure SEC source: 0001225208-12-008923 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,722 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 15, 2012 Filed Mar 19, 2012 12:48 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	2,236	$21.91	$48,990.76	Disclosure SEC source: 0001225208-12-007859 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,648 Underlying: Common Stock · 2,236 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
February 24, 2012 Filed Feb 27, 2012 23:14 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	7,483	$21.18	$158,489.94	Disclosure SEC source: 0001225208-12-005640 · doc4.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,880 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 24, 2012 Filed Feb 27, 2012 23:14 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	16,618	$0.00	$0.00	Disclosure SEC source: 0001225208-12-005640 · doc4.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,363 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 23, 2012 Filed Feb 27, 2012 23:14 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	144,033	$0.00 Strike: $21.03	$0.00	Disclosure SEC source: 0001225208-12-005640 · doc4.xml · derivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,033 Underlying: Common Stock · 144,033 shares Expires 2019-02-23 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 23, 2012 Filed Feb 27, 2012 23:14 UTC	PFIZER INC PFE · Entity 2863	GrantStock Appreciation Rights · Derivative	169,903	$0.00 Strike: $21.03	$0.00	Disclosure SEC source: 0001225208-12-005640 · doc4.xml · derivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,903 Underlying: Common Stock · 169,903 shares Expires 2017-02-23 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 23, 2012 Filed Feb 27, 2012 23:14 UTC	PFIZER INC PFE · Entity 2863	GrantCommon Stock	32,988	$0.00	$0.00	Disclosure SEC source: 0001225208-12-005640 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,745 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document
December 29, 2011 Filed Dec 30, 2011 21:04 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	72	$21.71	$1,563.12	Disclosure SEC source: 0001225208-11-027100 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,339 Underlying: Common Stock · 72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
December 15, 2011 Filed Dec 19, 2011 17:02 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	75	$21.14	$1,585.50	Disclosure SEC source: 0001225208-11-026537 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,267 Underlying: Common Stock · 75 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 30, 2011 Filed Dec 1, 2011 22:27 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	78	$20.07	$1,565.46	Disclosure SEC source: 0001225208-11-025589 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,192 Underlying: Common Stock · 78 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 15, 2011 Filed Nov 16, 2011 23:45 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	159	$19.87	$3,159.33	Disclosure SEC source: 0001225208-11-024984 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,114 Underlying: Common Stock · 159 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 31, 2011 Filed Nov 1, 2011 23:08 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	83	$19.26	$1,598.58	Disclosure SEC source: 0001225208-11-024120 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,955 Underlying: Common Stock · 83 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 14, 2011 Filed Oct 18, 2011 19:03 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	82	$19.04	$1,561.28	Disclosure SEC source: 0001225208-11-023473 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,872 Underlying: Common Stock · 82 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 30, 2011 Filed Oct 4, 2011 14:46 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	91	$17.68	$1,608.88	Disclosure SEC source: 0001225208-11-022592 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,790 Underlying: Common Stock · 91 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 15, 2011 Filed Sep 16, 2011 20:00 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	88	$18.49	$1,627.12	Disclosure SEC source: 0001225208-11-021835 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,699 Underlying: Common Stock · 88 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 31, 2011 Filed Sep 1, 2011 19:17 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	80	$18.98	$1,518.40	Disclosure SEC source: 0001225208-11-021088 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,611 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 15, 2011 Filed Aug 16, 2011 21:41 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	173	$18.34	$3,172.82	Disclosure SEC source: 0001225208-11-020053 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,531 Underlying: Common Stock · 173 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 03, 2011 Filed Aug 4, 2011 13:56 UTC	PFIZER INC PFE · Entity 2863	PurchaseCommon Stock	2,000	$17.82	$35,638.00	Disclosure SEC source: 0001225208-11-019273 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,404 Read SEC document
July 29, 2011 Filed Aug 2, 2011 16:57 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	79	$19.25	$1,520.75	Disclosure SEC source: 0001225208-11-019094 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,358 Underlying: Common Stock · 79 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
July 15, 2011 Filed Jul 19, 2011 14:27 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	82	$19.75	$1,619.50	Disclosure SEC source: 0001225208-11-018379 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,279 Underlying: Common Stock · 82 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
June 30, 2011 Filed Jul 5, 2011 14:44 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	73	$20.60	$1,503.80	Disclosure SEC source: 0001225208-11-017227 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,197 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
June 15, 2011 Filed Jun 16, 2011 19:08 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	85	$20.19	$1,716.15	Disclosure SEC source: 0001225208-11-016427 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,124 Underlying: Common Stock · 85 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
May 31, 2011 Filed Jun 1, 2011 18:20 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	72	$21.45	$1,544.40	Disclosure SEC source: 0001225208-11-015552 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,039 Underlying: Common Stock · 72 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
May 13, 2011 Filed May 16, 2011 17:34 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	144	$20.92	$3,012.48	Disclosure SEC source: 0001225208-11-014356 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,967 Underlying: Common Stock · 144 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 29, 2011 Filed May 2, 2011 21:36 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	73	$20.97	$1,530.81	Disclosure SEC source: 0001225208-11-012794 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,823 Underlying: Common Stock · 73 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
April 15, 2011 Filed Apr 18, 2011 18:58 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	77	$20.53	$1,580.81	Disclosure SEC source: 0001225208-11-011828 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,750 Underlying: Common Stock · 77 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 31, 2011 Filed Apr 4, 2011 16:26 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	80	$20.31	$1,624.80	Disclosure SEC source: 0001225208-11-010803 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,673 Underlying: Common Stock · 80 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
March 15, 2011 Filed Mar 16, 2011 20:11 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	1,495	$19.76	$29,541.20	Disclosure SEC source: 0001225208-11-009811 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,593 Underlying: Common Stock · 1,495 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
February 28, 2011 Filed Mar 2, 2011 00:45 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	2,552	$19.24	$49,100.48	Disclosure SEC source: 0001225208-11-007977 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,382 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
February 24, 2011 Filed Mar 1, 2011 02:39 UTC	PFIZER INC pfe · Entity 2863	GrantStock Appreciation Rights · Derivative	135,397	$0.00 Strike: $18.90	$0.00	Disclosure SEC source: 0000078003-11-000001 · primary_doc.xml · derivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,397 Underlying: Common Stock · 135,397 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document
February 24, 2011 Filed Mar 1, 2011 02:39 UTC	PFIZER INC pfe · Entity 2863	GrantStock Appreciation Rights · Derivative	163,551	$0.00 Strike: $18.90	$0.00	Disclosure SEC source: 0000078003-11-000001 · primary_doc.xml · derivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Underlying: Common Stock · 163,551 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document
February 24, 2011 Filed Mar 1, 2011 02:39 UTC	PFIZER INC pfe · Entity 2863	Tax withholdingCommon Stock	628	$18.90	$11,869.20	Disclosure SEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,934 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 24, 2011 Filed Mar 1, 2011 02:39 UTC	PFIZER INC pfe · Entity 2863	GrantCommon Stock	1,731	$0.00	$0.00	Disclosure SEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,562 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document
February 24, 2011 Filed Mar 1, 2011 02:39 UTC	PFIZER INC pfe · Entity 2863	GrantCommon Stock	37,057	$0.00	$0.00	Disclosure SEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,831 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document
February 23, 2011 Filed Feb 24, 2011 18:34 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	315	$18.76	$5,909.40	Disclosure SEC source: 0001225208-11-007062 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,774 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
January 31, 2011 Filed Feb 1, 2011 21:30 UTC	PFIZER INC PFE · Entity 2863	Tax withholdingCommon Stock	4,331	$18.22	$78,910.82	Disclosure SEC source: 0001225208-11-004432 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,291 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document
December 31, 2010 Filed Jan 3, 2011 22:20 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	74	$17.51	$1,295.74	Disclosure SEC source: 0001225208-11-000280 · doc4.xml · derivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,050 Underlying: Common Stock · 74 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.